Insider Buying: Sensus Healthcare (NASDAQ:SRTS) Director Acquires $182,728.00 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) Director Eric Sachetta acquired 81,575 shares of the firm’s stock in a transaction on Tuesday, November 17th. The shares were acquired at an average price of $2.24 per share, with a total value of $182,728.00. Following the completion of the purchase, the director owned 376,359 shares in the company, valued at approximately $843,044.16. This trade represents a 27.67% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Eric Sachetta also recently made the following trade(s):

  • On Monday, August 31st, Eric Sachetta acquired 27,304 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.54 per share, for a total transaction of $96,656.16.
  • On Friday, August 28th, Eric Sachetta acquired 37,537 shares of Sensus Healthcare stock. The stock was acquired at an average price of $3.44 per share, for a total transaction of $129,127.28.
  • On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The shares were acquired at an average cost of $3.18 per share, with a total value of $34,741.50.
  • On Wednesday, August 26th, Eric Sachetta bought 9,708 shares of Sensus Healthcare stock. The shares were acquired at an average price of $3.29 per share, with a total value of $31,939.32.
  • On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.25 per share, for a total transaction of $112,765.25.

Sensus Healthcare Trading Up 7.7%

SRTS traded up $0.18 during midday trading on Thursday, hitting $2.48. 69,188 shares of the company were exchanged, compared to its average volume of 105,719. The company’s 50 day simple moving average is $2.93 and its 200 day simple moving average is $3.41. The firm has a market capitalization of $40.75 million, a price-to-earnings ratio of -2.56 and a beta of 1.18. Sensus Healthcare, Inc. has a 1-year low of $2.14 and a 1-year high of $5.49.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $6.61 million. Sensus Healthcare had a negative return on equity of 24.95% and a negative net margin of 96.49%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Lake Street Capital dropped their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Weiss Ratings cut shares of Sensus Healthcare from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, November 13th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Sensus Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.83.

Read Our Latest Analysis on SRTS

Institutional Trading of Sensus Healthcare

Large investors have recently made changes to their positions in the company. Cetera Investment Advisers acquired a new stake in Sensus Healthcare during the 3rd quarter worth $48,000. EP Wealth Advisors LLC acquired a new stake in shares of Sensus Healthcare in the second quarter valued at about $49,000. Allworth Financial LP purchased a new position in shares of Sensus Healthcare in the third quarter worth about $209,000. BlackRock Inc. purchased a new position in shares of Sensus Healthcare in the second quarter worth about $252,000. Finally, Bank of New York Mellon Corp acquired a new position in Sensus Healthcare during the second quarter worth about $303,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc. develops and markets medical devices for the treatment of non-melanoma skin cancer and other skin conditions. Its products use superficial radiation therapy, which delivers low-energy X-rays to targeted areas of the skin. The company’s product portfolio includes the SRT-100 platform and related systems designed for use in clinical settings. Sensus positions these technologies as non-invasive treatment options for conditions including basal and squamous cell skin cancers and keloids.

Recommended Stories

Insider Buying and Selling by Quarter for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.